Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Carnegie Investment Counsel

Carnegie Investment Counsel trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,396 shares of the biopharmaceutical company’s stock after selling 152 shares during the period. Carnegie Investment Counsel’s holdings in Gilead Sciences were worth $2,992,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Mirador Capital Partners LP raised its holdings in shares of Gilead Sciences by 4.0% during the 4th quarter. Mirador Capital Partners LP now owns 13,723 shares of the biopharmaceutical company’s stock valued at $1,268,000 after buying an additional 528 shares during the period. USA Financial Formulas acquired a new stake in Gilead Sciences in the fourth quarter valued at approximately $1,539,000. BluePath Capital Management LLC raised its stake in shares of Gilead Sciences by 15.2% during the fourth quarter. BluePath Capital Management LLC now owns 9,854 shares of the biopharmaceutical company’s stock valued at $886,000 after purchasing an additional 1,299 shares during the period. Armstrong Advisory Group Inc. lifted its position in shares of Gilead Sciences by 14.2% during the fourth quarter. Armstrong Advisory Group Inc. now owns 1,606 shares of the biopharmaceutical company’s stock worth $148,000 after purchasing an additional 200 shares in the last quarter. Finally, Park Avenue Securities LLC boosted its stake in shares of Gilead Sciences by 31.4% in the fourth quarter. Park Avenue Securities LLC now owns 28,753 shares of the biopharmaceutical company’s stock valued at $2,656,000 after purchasing an additional 6,878 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently issued reports on GILD. Truist Financial lifted their price target on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research note on Friday, November 8th. Daiwa America upgraded Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Citigroup assumed coverage on Gilead Sciences in a research note on Thursday, November 14th. They set a “buy” rating and a $125.00 price objective for the company. Leerink Partnrs raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Finally, UBS Group raised their price target on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and an average target price of $97.96.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $91.84 on Friday. The firm’s 50 day moving average is $91.85 and its two-hundred day moving average is $83.81. The firm has a market capitalization of $114.46 billion, a P/E ratio of 1,020.44, a PEG ratio of 1.27 and a beta of 0.18. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. During the same period last year, the firm earned $2.29 EPS. The firm’s revenue was up 7.0% compared to the same quarter last year. Analysts anticipate that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 3.35%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 3,422.22%.

Insider Activity at Gilead Sciences

In other news, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the transaction, the insider now owns 99,599 shares in the company, valued at approximately $9,113,308.50. This trade represents a 20.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares in the company, valued at $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 456,234 shares of company stock worth $42,130,461 over the last quarter. 0.29% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.